Search
Chloroform
go.drugbank.com/drugs/DB11387ApprovedVet approvedWithdrawnIt is a colorless, sweet-smelling, dense liquid that is produced on a large scale as a precursor to PTFE and refrigerants, but the latter application is declining. … Chloroform is part of the FDA drug products withdrawn or removed from the market for reasons of safety or effectiveness.[L43942]
Categories: Compounds used in a research, industrial, or household settingEflornithine
go.drugbank.com/drugs/DB06243ApprovedInvestigationalWithdrawn[A262823,L49318] Subsequently, on December 14, 2023, the FDA approved eflornithine again but under the brand name IWILFIN as an oral maintenance therapy to reduce the risk of relapse in adult and pediatric … [A262839] In 1960 and 2000, the FDA approved eflornithine under the brand names ORNIDYL and VANIQUA for the treatment of African trypanosomiasis and hirsutism, respectively, but has since been discontinued
Fexinidazole
go.drugbank.com/drugs/DB12265Approvedall-oral treatment for first and second stage HAT caused by _T. brucei gambiense_. … Human African trypanosomiasis (HAT, also colloquially referred to as sleeping sickness), caused by _T. brucei gambiense_ and _T. brucei rhodesiense_, remains a moderate risk (>1/10,000 inhabitants per
Tebipenem pivoxil
go.drugbank.com/drugs/DB16840Approved[L57979] Carbapenems are the standard treatment for severe or resistant Gram-negative infections but had until now been available only intravenously, meaning patients with resistant complicated urinary … [L57980] Tebipenem pivoxil is the first oral carbapenem approved in the United States, creating an outpatient option for patients who have limited or no alternative oral therapy.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseVelpatasvir
go.drugbank.com/drugs/DB11613ApprovedInvestigationalGoals of therapy for Epclusa include the intent to cure, or achieve a sustained virologic response (SVR), after 12 weeks of daily therapy. … Velpatasvir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseNeon
go.drugbank.com/drugs/DB11589ApprovedIt is the fifth most abundant chemical element in the universe by mass but a rare element on Earth. … Neon may be used in the clinical setting as a diagnostic tracer gas in a gas analyzer for a lung diffusion test.
Mixtures: Lung Diffusion Test Mix No Ne Co, Co-NE-O2-N2 MixtureElbasvir
go.drugbank.com/drugs/DB11574Approved[A19593] Substitutions at amino acid positions 28, 30, 31, or 93 are known to confer resistance to elbasvir. … [A19626] In a computational target-based drug repurposing investigation published in April 2020, elbasvir was predicted to bind stably and preferentially to three proteins necessary for viral replication
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseIophendylate
go.drugbank.com/drugs/DB01187ApprovedIophendylate, which was never shown to be safe, was initially introduced for use in small amounts (1-2cc) for locating spinal tumors. … Iophendylate is a mixture of isomers used as contrast medium, mainly for brain and spinal cord visualization. Iophendylate is a myelographic oil-ester (U.S. Patent 2,348,231).
Categories: Compounds used in a research, industrial, or household settingEbola Zaire vaccine (live, attenuated)
go.drugbank.com/drugs/DB15595ApprovedInvestigational[L10854] By introducing the relatively inactive viral protein to the patient, the patient’s immune system learns to recognize and attack the virus if he or she is exposed to it in the future. … [L10866] In 2014, Merck Inc. signed a licensing agreement with NewLink for further development and marketing.
Fostamatinib
go.drugbank.com/drugs/DB12010ApprovedInvestigationalRecently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK … It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, L52150]. Fostamatinib has also been granted orphan drug status by the FDA [L2644].
Categories: Experimental Unapproved Treatments for COVID-19